JP2007523648A - 高リン酸化リソソーム酵素製剤及びそれらの使用 - Google Patents

高リン酸化リソソーム酵素製剤及びそれらの使用 Download PDF

Info

Publication number
JP2007523648A
JP2007523648A JP2006552376A JP2006552376A JP2007523648A JP 2007523648 A JP2007523648 A JP 2007523648A JP 2006552376 A JP2006552376 A JP 2006552376A JP 2006552376 A JP2006552376 A JP 2006552376A JP 2007523648 A JP2007523648 A JP 2007523648A
Authority
JP
Japan
Prior art keywords
disease
enzyme
type
sequence
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006552376A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007523648A5 (https=
Inventor
ザンケル，トッド
ディー． カッキス，エミル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomarin Pharmaceutical Inc
Original Assignee
Biomarin Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharmaceutical Inc filed Critical Biomarin Pharmaceutical Inc
Publication of JP2007523648A publication Critical patent/JP2007523648A/ja
Publication of JP2007523648A5 publication Critical patent/JP2007523648A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01003—Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006552376A 2004-02-06 2005-02-07 高リン酸化リソソーム酵素製剤及びそれらの使用 Pending JP2007523648A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54258604P 2004-02-06 2004-02-06
PCT/US2005/004345 WO2005077093A2 (en) 2004-02-06 2005-02-07 Manufacture of highly phosphorylated lysosomal enzymes and uses thereof

Publications (2)

Publication Number Publication Date
JP2007523648A true JP2007523648A (ja) 2007-08-23
JP2007523648A5 JP2007523648A5 (https=) 2008-03-27

Family

ID=34860323

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006552376A Pending JP2007523648A (ja) 2004-02-06 2005-02-07 高リン酸化リソソーム酵素製剤及びそれらの使用

Country Status (7)

Country Link
US (2) US20080014188A1 (https=)
EP (1) EP1720405A4 (https=)
JP (1) JP2007523648A (https=)
AU (1) AU2005211775B2 (https=)
BR (1) BRPI0507440A (https=)
CA (1) CA2556245A1 (https=)
WO (1) WO2005077093A2 (https=)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011509674A (ja) * 2008-01-18 2011-03-31 バイオマリン ファーマシューティカル インコーポレイテッド 高度にリン酸化された活性なヒトリソソームスルファターゼ酵素の製造およびそれの使用
WO2011108451A1 (ja) * 2010-03-01 2011-09-09 日本ケミカルリサーチ株式会社 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
WO2012157136A1 (ja) * 2011-05-19 2012-11-22 財団法人東京都医学総合研究所 リン酸化糖鎖を含有する組換えヒトサポシンｂタンパク質及びその用途
JP2013520184A (ja) * 2010-02-24 2013-06-06 ザイムネックス エー／エス 組み換えリソソームα−マンノシダーゼの生産および精製のための方法
JP2014517015A (ja) * 2011-06-10 2014-07-17 プロセラ インコーポレイテッド プロテアーゼを含有する医薬組成物およびリソソーム蓄積症の治療方法
US9138465B2 (en) 2011-04-28 2015-09-22 Osaka University Pharmaceutical composition for treating lysosomal storage disease
JP2016117754A (ja) * 2009-02-20 2016-06-30 ２−ビービービー メディシンズ ベスローテン フェンノートシャップ グルタチオンをベースとする薬物送達システム
JP2017537604A (ja) * 2014-09-30 2017-12-21 アミカス セラピューティックス インコーポレイテッド 炭水化物が増大している非常に強力な酸性アルファ−グルコシダーゼ
US12246062B2 (en) 2017-05-15 2025-03-11 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase
US12414985B2 (en) 2015-12-30 2025-09-16 Amicus Therapeutics, Inc. Augmented acid alpha-glucosidase for the treatment of Pompe disease

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
WO2003057179A2 (en) 2002-01-11 2003-07-17 Biomarin Pharmaceutical, Inc. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
EP2857036B1 (en) 2003-01-31 2016-12-21 Mount Sinai School of Medicine of New York University Combination therapy for treating protein deficiency disorders
EP1877099B1 (en) 2005-04-06 2012-09-19 Genzyme Corporation Therapeutic conjugates comprising a lysosomal enzyme, polysialic acid and a targeting moiety
EP3782655A1 (en) 2005-05-17 2021-02-24 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
WO2008089403A2 (en) 2007-01-18 2008-07-24 Genzyme Corporation Oligosaccharides comprising an aminooxy group and conjugates thereof
CA2696699A1 (en) * 2007-08-20 2009-02-26 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
US7722865B2 (en) 2008-01-18 2010-05-25 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
WO2009131698A2 (en) * 2008-04-23 2009-10-29 Iowa State University Research Foundation, Inc. PHOSPHORYLATED RECOMBINANT N-ACETYL-alpha-D- GLUCOSAMINIDASE (NaGlu) AND USES THEREOF
WO2010056746A1 (en) * 2008-11-11 2010-05-20 Amicus Therapeutics, Inc. Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease
CN102369023A (zh) 2008-12-16 2012-03-07 建新公司 寡糖-蛋白缀合物
JP5866117B2 (ja) * 2009-04-06 2016-02-17 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 分子を送達するための方法および材料
EP3679942A1 (en) 2009-06-17 2020-07-15 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
PT3103469T (pt) 2010-06-25 2021-03-04 Shire Human Genetic Therapies Administração de agentes terapêuticos no snc
JP6073783B2 (ja) 2010-06-25 2017-02-01 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド ヘパランｎ−スルファターゼのｃｎｓ送達のための方法および組成物
KR20230159646A (ko) 2010-06-25 2023-11-21 샤이어 휴먼 지네틱 테라피즈 인크. 이듀로네이트-2-설파타제의 cns 전달을 위한 방법들 및 조성물들
US20110318324A1 (en) * 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. Methods and compositions for cns delivery of b-galactocerebrosidase
LT2588130T (lt) 2010-06-25 2016-12-12 Shire Human Genetic Therapies, Inc. Terapinės priemonės pristatymas cns
HRP20191923T1 (hr) 2010-06-25 2020-01-10 Shire Human Genetic Therapies, Inc. Postupci i sastavi za isporuku arilsulfataze a u cns
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
KR101883803B1 (ko) 2011-01-20 2018-07-31 프로탈릭스 리미티드 식물 및 식물 세포에서 알파-갈락토시다제의 발현용 핵산 작제물
TW201307563A (zh) * 2011-05-19 2013-02-16 Shire Human Genetic Therapies 純化乙醯肝素－ｎ－硫酸酯酶之方法
CN103747807B (zh) 2011-07-05 2016-12-07 比奥阿赛斯技术有限公司 P97‑抗体缀合物和使用方法
AU2012294673B2 (en) 2011-08-05 2015-11-26 Bioasis Technologies Inc. p97 fragments with transfer activity
US20140377244A1 (en) 2011-12-23 2014-12-25 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
KR20230066482A (ko) 2012-03-07 2023-05-15 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
SMT202100136T1 (it) 2012-05-03 2021-05-07 Amicus Therapeutics Inc Regimi posologici per il trattamento della malattia di pompe
CA3140358A1 (en) 2012-07-31 2014-02-06 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
WO2014089487A1 (en) * 2012-12-07 2014-06-12 Shire Human Genetic Therapies, Inc. Methods and compositions for intrathecally administered treatment of mucupolysaccharidosis type iiia
AU2014243816B2 (en) 2013-03-13 2019-01-31 Bioasis Technologies Inc. Fragments of p97 and uses thereof
JP6603227B2 (ja) 2014-02-03 2019-11-06 バイオアシス テクノロジーズ インコーポレイテッド Ｐ９７融合タンパク質
DK3107562T3 (da) 2014-02-19 2019-12-16 Bioasis Technologies Inc P97-ids-fusionsproteiner
AU2015252906C1 (en) 2014-05-01 2020-09-17 Bioasis Technologies Inc. p97-polynucleotide conjugates
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
AU2017239641A1 (en) 2016-03-30 2018-10-18 Amicus Therapeutics, Inc. Formulations comprising recombinant acid alpha-glucosidase
TWI759291B (zh) * 2016-03-30 2022-04-01 美商阿米庫斯醫療股份有限公司 用於選擇高m6p重組蛋白之方法
CA3019354A1 (en) 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Method for selection of high m6p recombinant proteins
EA039750B1 (ru) * 2017-03-30 2022-03-10 Амикус Терапьютикс, Инк. Способ отбора рекомбинантных белков с высоким содержанием m6p
DK3635009T3 (da) 2017-06-07 2026-03-30 Regeneron Pharma Sammensætninger og fremgangsmåder til internalisering af enzymer
US12258597B2 (en) 2018-02-07 2025-03-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
BR112020023145A2 (pt) 2018-05-17 2021-02-02 Regeneron Pharmaceuticals, Inc. anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto
JP2023507575A (ja) 2019-12-20 2023-02-24 コデクシス， インコーポレイテッド 操作された酸性アルファ－グルコシダーゼバリアント
EP4735591A2 (en) * 2023-06-30 2026-05-06 Crosswalk Therapeutics, Inc. Engineered acid alpha-glucosidase variants

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003509043A (ja) * 1999-09-14 2003-03-11 ウイリアム、エム．キャンフィールド リソソームターゲティング経路酵素

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US5186941A (en) * 1983-05-06 1993-02-16 Vestar, Inc. Vesicle formulation for the controlled release of therapeutic agents
TW492882B (en) 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003509043A (ja) * 1999-09-14 2003-03-11 ウイリアム、エム．キャンフィールド リソソームターゲティング経路酵素

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011509674A (ja) * 2008-01-18 2011-03-31 バイオマリン ファーマシューティカル インコーポレイテッド 高度にリン酸化された活性なヒトリソソームスルファターゼ酵素の製造およびそれの使用
JP2016117754A (ja) * 2009-02-20 2016-06-30 ２−ビービービー メディシンズ ベスローテン フェンノートシャップ グルタチオンをベースとする薬物送達システム
US10159718B2 (en) 2010-02-24 2018-12-25 Chiesi Farmaceutici S.P.A Process for production and purification of recombinant lysosomal alpha-mannosidase
JP2013520184A (ja) * 2010-02-24 2013-06-06 ザイムネックス エー／エス 組み換えリソソームα−マンノシダーゼの生産および精製のための方法
WO2011108451A1 (ja) * 2010-03-01 2011-09-09 日本ケミカルリサーチ株式会社 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
JPWO2011108451A1 (ja) * 2010-03-01 2013-06-27 日本ケミカルリサーチ株式会社 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
US9138465B2 (en) 2011-04-28 2015-09-22 Osaka University Pharmaceutical composition for treating lysosomal storage disease
JP5959114B2 (ja) * 2011-05-19 2016-08-02 学校法人 明治薬科大学 リン酸化糖鎖を含有する組換えヒトサポシンｂタンパク質及びその用途
WO2012157136A1 (ja) * 2011-05-19 2012-11-22 財団法人東京都医学総合研究所 リン酸化糖鎖を含有する組換えヒトサポシンｂタンパク質及びその用途
JP2014517015A (ja) * 2011-06-10 2014-07-17 プロセラ インコーポレイテッド プロテアーゼを含有する医薬組成物およびリソソーム蓄積症の治療方法
JP2017537604A (ja) * 2014-09-30 2017-12-21 アミカス セラピューティックス インコーポレイテッド 炭水化物が増大している非常に強力な酸性アルファ−グルコシダーゼ
JP2021011489A (ja) * 2014-09-30 2021-02-04 アミカス セラピューティックス インコーポレイテッド 炭水化物が増大している非常に強力な酸性アルファ−グルコシダーゼ
JP7225176B2 (ja) 2014-09-30 2023-02-20 アミカス セラピューティックス インコーポレイテッド 炭水化物が増大している非常に強力な酸性アルファ－グルコシダーゼ
JP2023078118A (ja) * 2014-09-30 2023-06-06 アミカス セラピューティックス インコーポレイテッド 炭水化物が増大している非常に強力な酸性アルファ－グルコシダーゼ
JP7834671B2 (ja) 2014-09-30 2026-03-24 アミカス セラピューティックス インコーポレイテッド 炭水化物が増大している非常に強力な酸性アルファ－グルコシダーゼ
US12414985B2 (en) 2015-12-30 2025-09-16 Amicus Therapeutics, Inc. Augmented acid alpha-glucosidase for the treatment of Pompe disease
US12246062B2 (en) 2017-05-15 2025-03-11 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase

Also Published As

Publication number Publication date
EP1720405A4 (en) 2008-08-27
EP1720405A2 (en) 2006-11-15
US20080014188A1 (en) 2008-01-17
WO2005077093A3 (en) 2005-12-15
US20090191178A1 (en) 2009-07-30
AU2005211775A1 (en) 2005-08-25
AU2005211775B2 (en) 2009-10-08
CA2556245A1 (en) 2005-08-25
BRPI0507440A (pt) 2007-07-10
WO2005077093A2 (en) 2005-08-25

Similar Documents

Publication Publication Date Title
JP2007523648A (ja) 高リン酸化リソソーム酵素製剤及びそれらの使用
US12188058B2 (en) Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
JP6030553B2 (ja) 高度にリン酸化された活性なヒトｎ−アセチルガラクトサミン−６−スルファターゼの製造およびその使用
US7722865B2 (en) Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
HK40115219A (en) Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
HK1244505B (en) Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
HK1185549B (en) Manufacture of active highly phosphorylated human n-acetylgalactosamine-6-sulfatase and uses thereof
HK1185549A (en) Manufacture of active highly phosphorylated human n-acetylgalactosamine-6-sulfatase and uses thereof
HK1144446A (en) Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101012

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110308